These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 37932776)
1. No obvious effect on mortality from a patient choice reform expanding access to opioid disorder treatment - results from a natural experiment of policy change in Sweden. Håkansson A; Janfada-Baloo S; Berge J Subst Abuse Treat Prev Policy; 2023 Nov; 18(1):64. PubMed ID: 37932776 [TBL] [Abstract][Full Text] [Related]
2. Changes in opioid-related deaths following increased access to opioid substitution treatment. Andersson L; Håkansson A; Berge J; Johnson B Subst Abuse Treat Prev Policy; 2021 Feb; 16(1):15. PubMed ID: 33568184 [TBL] [Abstract][Full Text] [Related]
3. Association of Medicaid Expansion With Opioid Overdose Mortality in the United States. Kravitz-Wirtz N; Davis CS; Ponicki WR; Rivera-Aguirre A; Marshall BDL; Martins SS; Cerdá M JAMA Netw Open; 2020 Jan; 3(1):e1919066. PubMed ID: 31922561 [TBL] [Abstract][Full Text] [Related]
4. Access to methadone clinics and opioid overdose deaths in Georgia: A geospatial analysis. Anwar T; Duever M; Jayawardhana J Drug Alcohol Depend; 2022 Sep; 238():109565. PubMed ID: 35839618 [TBL] [Abstract][Full Text] [Related]
5. Systematic Evaluation of State Policy Interventions Targeting the US Opioid Epidemic, 2007-2018. Lee B; Zhao W; Yang KC; Ahn YY; Perry BL JAMA Netw Open; 2021 Feb; 4(2):e2036687. PubMed ID: 33576816 [TBL] [Abstract][Full Text] [Related]
6. Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder. Haffajee RL; Lin LA; Bohnert ASB; Goldstick JE JAMA Netw Open; 2019 Jun; 2(6):e196373. PubMed ID: 31251376 [TBL] [Abstract][Full Text] [Related]
7. Targeting community-based naloxone distribution using opioid overdose death rates: A descriptive analysis of naloxone rescue kits and opioid overdose deaths in Massachusetts and Rhode Island. Zang X; Macmadu A; Krieger MS; Behrends CN; Green TC; Morgan JR; Murphy SM; Nolen S; Walley AY; Schackman BR; Marshall BD Int J Drug Policy; 2021 Dec; 98():103435. PubMed ID: 34482264 [TBL] [Abstract][Full Text] [Related]
8. Trends and Characteristics of Buprenorphine-Involved Overdose Deaths Prior to and During the COVID-19 Pandemic. Tanz LJ; Jones CM; Davis NL; Compton WM; Baldwin GT; Han B; Volkow ND JAMA Netw Open; 2023 Jan; 6(1):e2251856. PubMed ID: 36662523 [TBL] [Abstract][Full Text] [Related]
9. The Effect of Naloxone Access Laws on Fatal Synthetic Opioid Overdose Fatality Rates. Tabatabai M; Cooper RL; Wilus DM; Edgerton RD; Ramesh A; MacMaster SA; Patel PN; Singh KP J Prim Care Community Health; 2023; 14():21501319221147246. PubMed ID: 36625264 [TBL] [Abstract][Full Text] [Related]
10. Individual and county-level variation in outcomes following non-fatal opioid-involved overdose. Lowder EM; Amlung J; Ray BR J Epidemiol Community Health; 2020 Apr; 74(4):369-376. PubMed ID: 31919146 [TBL] [Abstract][Full Text] [Related]
11. Local health departments and the implementation of evidence-based policies to address opioid overdose mortality. Feuerstein-Simon R; Lowenstein M; Sharma M; Dupuis R; Luna Marti X; Cannuscio CC Subst Abus; 2020; 41(4):468-474. PubMed ID: 32213045 [TBL] [Abstract][Full Text] [Related]
12. Disparities in opioid overdose survival and naloxone administration in Pennsylvania. Holmes LM; Rishworth A; King BH Drug Alcohol Depend; 2022 Sep; 238():109555. PubMed ID: 35810621 [TBL] [Abstract][Full Text] [Related]
13. Statewide Policy to Increase Provision of Take-Home Naloxone at Emergency Department Visits for Opioid Overdose, Rhode Island, 2018‒2019. Griffith J; Yorlets RR; Chambers LC; Davis CS; Wentz A; Beaudoin FL; Baird J; Samuels EA Am J Public Health; 2023 Apr; 113(4):372-377. PubMed ID: 36745856 [TBL] [Abstract][Full Text] [Related]
15. Urban scaling of opioid overdose deaths in the USA: a cross-sectional study in three periods between 2005 and 2017. Mullachery PH; Lankenau S; Diez Roux AV; Li R; Henson RM; Bilal U BMJ Open; 2022 Mar; 12(3):e048831. PubMed ID: 35241464 [TBL] [Abstract][Full Text] [Related]
16. Take-home naloxone programs for suspected opioid overdose in community settings: a scoping umbrella review. Moustaqim-Barrette A; Dhillon D; Ng J; Sundvick K; Ali F; Elton-Marshall T; Leece P; Rittenbach K; Ferguson M; Buxton JA BMC Public Health; 2021 Mar; 21(1):597. PubMed ID: 33771150 [TBL] [Abstract][Full Text] [Related]
17. Provider perceptions of medication for opioid used disorder (MOUD): A qualitative study in communities with high opioid overdose death rates. Paul N; Kennedy AJ; Taubenberger S; Chang JC; Hacker K Subst Abus; 2022; 43(1):742-748. PubMed ID: 35100094 [TBL] [Abstract][Full Text] [Related]
18. Comparison between buprenorphine provider availability and opioid deaths among US counties. Jones CW; Christman Z; Smith CM; Safferman MR; Salzman M; Baston K; Haroz R J Subst Abuse Treat; 2018 Oct; 93():19-25. PubMed ID: 30126537 [TBL] [Abstract][Full Text] [Related]
19. Legal System Involvement and Opioid-Related Overdose Mortality in U.S. Department of Veterans Affairs Patients. Finlay AK; Palframan KM; Stimmel M; McCarthy JF Am J Prev Med; 2022 Jan; 62(1):e29-e37. PubMed ID: 34521559 [TBL] [Abstract][Full Text] [Related]